FOLI, ANDREA
 Distribuzione geografica
Continente #
NA - Nord America 324
AS - Asia 248
EU - Europa 227
AF - Africa 2
OC - Oceania 1
Totale 802
Nazione #
US - Stati Uniti d'America 322
CN - Cina 228
IE - Irlanda 128
FI - Finlandia 36
DE - Germania 29
IT - Italia 17
JP - Giappone 11
SE - Svezia 6
GB - Regno Unito 4
IN - India 4
FR - Francia 3
SG - Singapore 3
CA - Canada 2
ES - Italia 2
IR - Iran 2
AT - Austria 1
AU - Australia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
SL - Sierra Leone 1
Totale 802
Città #
Dublin 128
Chandler 106
Nanjing 57
Beijing 45
Helsinki 22
Jacksonville 22
Nanchang 22
Ashburn 19
Shenyang 18
Princeton 17
Hebei 16
Lawrence 16
Tianjin 15
Changsha 13
Medford 13
Pavia 13
Wilmington 12
Shanghai 11
Tokyo 11
Jiaxing 10
Hangzhou 6
Piscataway 6
Norwalk 4
Pune 4
Tamm 4
Falkenstein 3
Woodbridge 3
Zhengzhou 3
Chicago 2
Fuzhou 2
New York 2
Ningbo 2
Singapore 2
Taizhou 2
Vinovo 2
Ann Arbor 1
Brno 1
Cairo 1
Cervera del Rio Alhama 1
Dearborn 1
Fairfield 1
Freetown 1
Haikou 1
Houston 1
Jinan 1
London 1
Markham 1
Nagold 1
Orange 1
Redwood City 1
Saint-Alexis-de-Matapedia 1
San Francisco 1
Seattle 1
Shiraz 1
Sydney 1
Vienna 1
Totale 654
Nome #
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 64
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 63
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 62
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 57
A patient with AL amyloidosis with negative free light chain results 55
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 52
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 52
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 51
Prognostication of survival and progression to dialysis in AA amyloidosis 48
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 47
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 46
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 45
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 43
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 43
A practical approach to the diagnosis of systemic amyloidoses 35
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 31
null 30
null 28
Totale 852
Categoria #
all - tutte 3.498
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.498


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020222 65 107 0 0 1 0 2 0 1 32 11 3
2020/202134 4 0 0 0 0 1 1 8 16 3 0 1
2021/202268 0 0 0 0 3 0 1 7 4 3 7 43
2022/2023309 33 32 7 18 21 31 0 10 149 1 6 1
2023/2024125 18 23 4 9 10 20 0 6 0 3 16 16
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 852